Last reviewed · How we verify
The Egyptian IVF-ET Center — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Clomiphene citrate / hCG | Clomiphene citrate / hCG | marketed | Ovulation induction agent / Gonadotropin-releasing hormone analog combination | Estrogen receptor (clomiphene); LH receptor (hCG) | Reproductive Medicine / Fertility | |
| Metformin / clomid / hCG | Metformin / clomid / hCG | marketed | Combination fertility agent (insulin sensitizer + ovulation inducer + gonadotropin) | Reproductive Medicine / Fertility |
Therapeutic area mix
- Reproductive Medicine / Fertility · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for The Egyptian IVF-ET Center:
- The Egyptian IVF-ET Center pipeline updates — RSS
- The Egyptian IVF-ET Center pipeline updates — Atom
- The Egyptian IVF-ET Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). The Egyptian IVF-ET Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-egyptian-ivf-et-center. Accessed 2026-05-16.